2.2 Staging, Grading, & Surgical Oncology Interventions

2.2 Staging, Grading, & Surgical Oncology Interventions

Accurate classification of malignant neoplasms through anatomical staging and histological grading is essential for establishing prognosis, formulating multi-modal oncologic treatment plans, and predicting treatment-related toxicities. Surgical resection remains the primary curative modality for most localized solid tumors; however, extensive anatomical resections throughout the gastrointestinal (GI) tract induce profound metabolic, structural, and nutritional sequelae.

---

Cancer Staging & Histological Grading

The AJCC TNM Staging System

The American Joint Committee on Cancer (AJCC) TNM Staging System (8th Edition) provides the universal standardized framework for classifying the anatomical extent of solid tumors at diagnosis.

• T (Primary Tumor): Refers to the size, radial extent, and depth of local invasion of the primary tumor.
  • TX: Primary tumor cannot be evaluated; T0: No evidence of primary tumor; Tis: Carcinoma in situ (non-invasive lesion confined to epithelial basement membrane).
  • T1, T2, T3, T4: Progressive increase in primary tumor size, depth of wall invasion, or anatomical extension into adjacent organs.
• N (Regional Lymph Nodes): Describes the presence, number, and location of regional lymph node metastases.
  • NX: Regional nodes cannot be evaluated; N0: No regional lymph node metastasis.
  • N1, N2, N3: Progressive increase in the number, size, or anatomical distance of involved regional lymph nodes.
• M (Distant Metastasis): Indicates the presence or absence of distant hematogenous or non-regional lymphatic spread.
  • M0: No distant metastasis; M1: Distant metastasis present (e.g., liver, lung, bone, brain, distant peritoneum).

+---------------------------------------------------------------------------------------------+
|                                 STAGE GROUPING OVERVIEW                                     |
| Stage 0   | Carcinoma in situ (Tis N0 M0) - Non-invasive; 100% localized.                   |
| Stage I   | Small primary tumor without nodal involvement (T1-T2 N0 M0) - Curative intent.  |
| Stage II  | Larger primary tumor with local tissue extension (T3-T4 N0 M0) - Curative intent. |
| Stage III | Regional lymph node involvement (Any T, N1-N3, M0) - Multi-modal therapy.       |
| Stage IV  | Distant Metastatic Spread (Any T, Any N, M1) - Systemic; Palliative intent.     |
+---------------------------------------------------------------------------------------------+

Histological Grading

While staging describes where the tumor is located anatomically, histological grading evaluates microscopic cellular differentiation—the degree to which neoplastic cells resemble normal host tissue cells.

---

Surgical Resections & Medical Nutrition Therapy (MNT)

Surgical procedures involving the upper, middle, and lower GI tract alter mechanical digestion, nutrient absorption, GI transit time, and neurohumoral gut hormone feedback mechanisms.

1. Head & Neck Surgery (Radical Neck Dissection / Total Laryngectomy)

• Surgical Scope: Resection of oral cavity, pharyngeal, or laryngeal structures; radical neck dissection removes cervical lymph nodes, sternocleidomastoid muscle, and internal jugular vein.
• Anatomical Sequelae: Loss of masticatory function, glossal impairment, trismus (inability to open jaw wide), altered swallowing biomechanics, loss of airway protection (total laryngectomy creates a permanent tracheostoma).
• MNT Complications: Severe mechanical and neurogenic dysphagia, elevated aspiration risk, profound oral intake reduction, rapid involuntary weight loss.
• MNT Interventions:
  • Prophylactic placement of enteral nutrition (EN) access (PEG or RIG) prior to complex head and neck surgery or definitive chemoradiation when severe mucositis or dysphagia is anticipated.
  • Speech-Language Pathologist (SLP) dysphagia evaluations for International Dysphagia Diet Standardisation Initiative (IDDSI) bolus consistency modifications (pureed foods, thickened liquids).
  • Swallowing rehabilitation exercises (e.g., Mendelsohn maneuver, supraglottic swallow) to preserve pharyngeal muscle tone.

2. Total & Subtotal Gastrectomy

• Surgical Scope: Resection of the entire stomach (total gastrectomy) or distal 2/3 (subtotal gastrectomy) with reconstruction via Roux-en-Y esophagojejunostomy or gastrojejunostomy.
• Anatomical Sequelae: Total loss of gastric reservoir capacity, loss of gastric acid secretion (achlorhydria), complete absence of Intrinsic Factor (IF) secretion from gastric parietal cells, disruption of pyloric sphincter control.
• MNT Complications:
  • Dumping Syndrome (Early & Late): Early dumping occurs 10–30 minutes postprandially due to hyperosmolar chyme rapidly entering the jejunum, causing intraluminal fluid shifts, abdominal cramping, nausea, tachycardia, and diaphoresis. Late dumping occurs 1–3 hours postprandially due to rapid carbohydrate absorption triggering reactive hyperinsulinemic hypoglycemia.
  • Vitamin B12 Deficiency: Universal following total gastrectomy due to complete loss of Intrinsic Factor (IF), which is mandatory for B12 receptor binding and absorption in the terminal ileum.
  • Malabsorption & Anemia: Fat malabsorption (steatorrhea) due to pancreatic-cibal asynchrony, and iron deficiency anemia caused by loss of gastric acid required to reduce non-heme ferric iron ($Fe^{3+}$) to absorbable ferrous iron ($Fe^{2+}$).
• MNT Interventions:
  • Post-gastrectomy dietary protocol: Small, frequent meals (6–8 meals daily); strict separation of liquids from solids (avoid fluids 30 min before and after meals); elimination of concentrated simple sugars.
  • Mandatory lifelong Vitamin B12 replacement: 1,000 mcg IM/SC monthly or 1,000–2,000 mcg sublingual daily.
  • Calcium citrate supplementation (absorbed independently of gastric acid) and oral/IV iron replacement.

3. Pancreaticoduodenectomy (Whipple Procedure)

• Surgical Scope: Resection of the pancreatic head, duodenum, distal stomach (antrum), gallbladder, and common bile duct, followed by pancreaticojejunostomy, choledochojejunostomy, and gastrojejunostomy.
• Anatomical Sequelae: Severe reduction in pancreatic exocrine enzyme output, loss of duodenal absorptive surface area, altered biliary drainage.
• MNT Complications:
  • Pancreatic Exocrine Insufficiency (PEI): Maldigestion of dietary fat, steatorrhea (>7g fecal fat/24 hr), oily bulky stools, abdominal cramping, weight loss, and fat-soluble vitamin (A, D, E, K) deficiencies.
  • Delayed Gastric Emptying (DGE): Post-operative gastroparesis occurring in 25–40% of Whipple patients.
  • Pancreatogenic (Type 3c) Diabetes Mellitus: Loss of endocrine pancreatic beta-cell mass.
• MNT Interventions:
  • Pancreatic Enzyme Replacement Therapy (PERT): Initial dosing of 500–2,500 lipase units/kg body weight per meal (or ~25,000–50,000 lipase units per main meal, half-dose for snacks). Enzymes must be swallowed with the first bite of fat-containing food.
  • Co-administration of Proton Pump Inhibitors (PPIs) to prevent gastric acid inactivation of enteric-coated PERT microspheres in the proximal intestine.
  • Routine monitoring of serum 25-OH Vitamin D and Retinol levels.

4. Esophagectomy (Transthoracic / Transhiatal)

• Surgical Scope: Resection of the esophagus with creation of a gastric conduit ("gastric pull-up") or colonic interposition.
• Anatomical Sequelae: Bilateral vagotomy, intrathoracic positioning of stomach conduit, loss of lower esophageal sphincter (LES).
• MNT Complications: Early satiety, severe gastroesophageal reflux, delayed conduit emptying, anastomotic leak, and chylothorax (disruption of the thoracic duct leading to chyle leak into the pleural cavity).
• MNT Interventions:
  • Placement of intraoperative Jejunostomy Tube (J-tube) for early post-operative enteral feeding, maintaining nocturnal tube feedings to permit daytime oral intake trials.
  • Position head of bed elevated >30–45 degrees during and after meals to prevent nocturnal regurgitation and aspiration.
  • Chylothorax Protocol: Strict Very Low-Fat Diet (<10g fat/day) supplemented with Medium-Chain Triglyceride (MCT) oil (which enters portal circulation directly, bypassing lymphatic transport), or complete bowel rest with Total Parenteral Nutrition (TPN) to reduce thoracic duct lymphatic flow.

5. Colectomy, Ileostomy & Colostomy

• Surgical Scope: Resection of colon segments (colectomy) with creation of an abdominal wall stoma.
• Anatomical Sequelae: Loss of colonic water and electrolyte absorption capacity.
• MNT Complications:
  • High-Output Ileostomy: Stoma output exceeding 1,000–1,500 mL/day, causing rapid dehydration, hyponatremia, hypokalemia, and prerenal azotemia.
  • B12 and bile acid malabsorption if >50 cm of terminal ileum is resected.
• MNT Interventions:
  • High-output ileostomy management: Restrict hypotonic free water, soda, and coffee; prescribe isotonic Oral Rehydration Solutions (ORS) containing sodium (75–90 mEq/L) and glucose.
  • Soluble fiber supplementation (psyllium 3.5–7.0g daily) to increase stoma stool viscosity.
  • Anti-motility agents (loperamide 2–4 mg 30 min prior to meals and at bedtime; diphenoxylate/atropine).